ANEBULO PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $4.3M | $3.5M | $5.6M | $3.0M | $2.3M | — |
| SG&A Expense | $4.9M | $4.8M | $6.2M | $3.9M | $1.3M | — |
| Operating Income | $-9.2M | $-8.3M | $-11.8M | $-6.8M | $-3.6M | — |
| Operating Margin | — | — | — | — | — | — |
| Interest Expense | $400.0K | $200.0K | — | — | $11.8K | — |
| Pretax Income | — | — | — | — | $-3.6M | — |
| Income Tax Expense | — | — | — | — | — | — |
| Net Income | $-8.5M | $-8.2M | $-11.7M | $-6.8M | $-30.3M | — |
| Net Margin | — | — | — | — | — | — |
| EPS (Basic) | $-0.25 | $-0.32 | $-0.47 | $0.29 | $-2.83 | — |
| EPS (Diluted) | $-0.25 | $-0.32 | $-0.47 | $0.29 | $-2.83 | — |
| Shares Outstanding (Basic) | 33.8M | 25.8M | 25.1M | 23.3M | 13.6M | 12.0M |
| Shares Outstanding (Diluted) | 33.8M | 25.8M | 25.1M | 23.3M | 13.6M | 12.0M |
| Dividends Per Share | — | — | — | — | — | — |